Angelika Schütz
Research Subjects
Research Interests
Angelika Schütz has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Caroline Schwarz
Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria; Department of Internal Medicine IV, Klinik Ottakring, Vienna, Austria
5 shared publications - Hans Haltmayer
Suchthilfe Wien gGmbH, Ambulatorium Suchthilfe Wien, Vienna, Austria
5 shared publications - Michael Gschwantler
Klinik Ottakring, Department of Internal Medicine IV, Vienna, Austria
5 shared publications - Thomas Reiberger
Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
5 shared publications - Cornelia Schwanke
Suchthilfe Wien gGmbH, Ambulatorium Suchthilfe Wien, Vienna, Austria
4 shared publications - Raphael Schubert
Suchthilfe Wien gGmbH, Ambulatorium Suchthilfe Wien, Vienna, Austria
4 shared publications
Latest Publications
- Open Access
- 27 July 2023
- Published by Elsevier in Journal of Virus Eradication
- Vol. 9 (3) , 100338
CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers
- 27 July 2023
- Published by Elsevier in Journal of Virus Eradication
- Vol. 9 (3) , 100338
Open AccessCHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers
- Open Access
- 1 March 2023
- Published by Elsevier in Journal of Virus Eradication
- Vol. 9 (1) , 100319
Combining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral therapy
- 1 March 2023
- Published by Elsevier in Journal of Virus Eradication
- Vol. 9 (1) , 100319
Open AccessCombining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral therapy
- Open Access
- 3 November 2022
- Published by Elsevier in SSRN Electronic Journal
Combining Treatment for Chronic Hepatitis C with Opioid Agonist Therapy is an Effective Microelimination Strategy for People Who Inject Drugs with High Risk of Non-Adherence to Antiviral Therapy
Background & Aims: Despite effective direct-acting antivirals (DAAs), hepatitis C virus (HCV) prevalence is high among people who inject drugs (PWIDs) and non-adherence to therapy remains a major obstacle towards HCV elimination in this subpopulation. To overcome this, we combined ongoing opioid agonist therapy (OAT) with direct-acting antivirals (DAA) in a directly-observed therapy (DOT) setting. Method: From September 2014 until January 2021 PWIDs at high risk for non-adherence to DAA therapy were included in this microelimination project. PWIDs received HCV treatment alongside their OAT under supervision of healthcare workers in a pharmacy or low-threshold facility. Results: In total, 522 HCV-RNA-positive PWIDs (400 men, 76.6%; median age: 38 years [IQR 12], HIV: 4.4%; HBV: 1.3%) were included. Of these, 308/491 patients (62.7%) reported ongoing IDU (intravenous drug use). Following the concept of DOT, adherence to DAA treatment was excellent (missed appointments: 90/25,792, 0.4%). Forty-one (7.9%) patients were lost to follow-up. Two (0.4%) patients died due to reasons unrelated to DAA treatment. SVR12 was achieved in 457/461 (99.1%; 95% CI: 98.3-100.0%) patients, while only 4/461 (0.9%) patients showed treatment failure (modified intention-to-treat, mITT). Over a median follow-up of 24 (IQR 27) weeks, reinfections were observed in 27/457 (5.9%) patients. Conclusions: Coupling DAA treatment to OAT in a DOT setting resulted in SVR12 rates greater than 99% in PWIDs at high risk for non-adherence to therapy despite high rates of IDU. Importantly, only 7.9% of the patients were lost to follow-up, but finished DAA therapy. Competing Intrerest Statement: Michael Schwarz, Austria (schwarz.medizin@gmail.com): received speaking honoraria from BMS and travel support from BMS, AbbVie, Gilead, and MSD. - Caroline Schwarz, Austria (schwarz.caroline1990@gmail.com): received travel support from Gilead, Abbvie, and Gebro; speaking honoraria from Abbvie and Gilead; and served as a consultant for Gilead. Angelika Schütz, Austria (angelika.schuetz@suchthilfe.at): no conflicts of interest. Cornelia Schwanke, Austria (cornelia.schwanke@suchthilfe.at): no conflicts of interest. Eva Krabb, Austria (eva.krabb@suchthilfe.at) no conflicts of interest. Raphael Schubert, Austria (raphael.schubert@outlook.at): received travel support from Gilead. Sophie-Therese Liebich, Austria (sophie-therese.liebich@suchthilfe.at): no conflicts of interest. David Bauer (david.bauer@meduniwien.ac.at): received travel support from Gilead and Abbvie and speaker fees from Abbvie. Lukas Burghart (lukas.burghart@gesundheitsverbund.at): no conflicts of interest. Leonard Brinkmann (leonard-ruben.brinkmann@gesundheitsverbund.at): no conflicts of interest. Enisa Gutic, Austria (enisa.gutic@extern.gesundheitsverbund.at): received travel support from Gilead and AbbVie. Thomas Reiberger, Austria (thomas.reiberger@meduniwien.ac.at): received grant support from Abbvie, Boehringer-Ingelheim, Gilead, MSD, Philips Healthcare, Gore; speaking honoraria from Abbvie, Gilead, Gore, Intercept, Roche, MSD; consulting/advisory board fee from Abbvie, Bayer, Boehringer-Ingelheim, Gilead, Intercept, MSD, Siemens; and travel support from Boehringer-Ingelheim, Gilead and Roche. Hans Haltmayer, Austria (hans.haltmayer@suchthilfe.at): no conflicts of interest. - Michael Gschwantler, Austria (michael.gschwantler@gesundheitsverbund.at): received grant support from Abbvie, Gilead and MSD; speaking honoraria from Abbvie, Gilead, Intercept, Janssen, BMS, Roche, Norgine, AstraZeneca, Falk, Shionogi, and MSD; consulting/advisory board fees from Abbvie, Gilead, Intercept, Janssen, BMS, Roche, Alnylam, Norgine, AstraZeneca, Falk, Shionogi and MSD; and travel support from Abbvie and Gilead.
- 3 November 2022
- Published by Elsevier in SSRN Electronic Journal
Open AccessCombining Treatment for Chronic Hepatitis C with Opioid Agonist Therapy is an Effective Microelimination Strategy for People Who Inject Drugs with High Risk of Non-Adherence to Antiviral Therapy
Background & Aims: Despite effective direct-acting antivirals (DAAs), hepatitis C virus (HCV) prevalence is high among people who inject drugs (PWIDs) and non-adherence to therapy remains a major obstacle towards HCV elimination in this subpopulation. To overcome this, we combined ongoing opioid agonist therapy (OAT) with direct-acting antivirals (DAA) in a directly-observed therapy (DOT) setting. Method: From September 2014 until January 2021 PWIDs at high risk for non-adherence to DAA therapy were included in this microelimination project. PWIDs received HCV treatment alongside their OAT under supervision of healthcare workers in a pharmacy or low-threshold facility. Results: In total, 522 HCV-RNA-positive PWIDs (400 men, 76.6%; median age: 38 years [IQR 12], HIV: 4.4%; HBV: 1.3%) were included. Of these, 308/491 patients (62.7%) reported ongoing IDU (intravenous drug use). Following the concept of DOT, adherence to DAA treatment was excellent (missed appointments: 90/25,792, 0.4%). Forty-one (7.9%) patients were lost to follow-up. Two (0.4%) patients died due to reasons unrelated to DAA treatment. SVR12 was achieved in 457/461 (99.1%; 95% CI: 98.3-100.0%) patients, while only 4/461 (0.9%) patients showed treatment failure (modified intention-to-treat, mITT). Over a median follow-up of 24 (IQR 27) weeks, reinfections were observed in 27/457 (5.9%) patients. Conclusions: Coupling DAA treatment to OAT in a DOT setting resulted in SVR12 rates greater than 99% in PWIDs at high risk for non-adherence to therapy despite high rates of IDU. Importantly, only 7.9% of the patients were lost to follow-up, but finished DAA therapy. Competing Intrerest Statement: Michael Schwarz, Austria (schwarz.medizin@gmail.com): received speaking honoraria from BMS and travel support from BMS, AbbVie, Gilead, and MSD. - Caroline Schwarz, Austria (schwarz.caroline1990@gmail.com): received travel support from Gilead, Abbvie, and Gebro; speaking honoraria from Abbvie and Gilead; and served as a consultant for Gilead. Angelika Schütz, Austria (angelika.schuetz@suchthilfe.at): no conflicts of interest. Cornelia Schwanke, Austria (cornelia.schwanke@suchthilfe.at): no conflicts of interest. Eva Krabb, Austria (eva.krabb@suchthilfe.at) no conflicts of interest. Raphael Schubert, Austria (raphael.schubert@outlook.at): received travel support from Gilead. Sophie-Therese Liebich, Austria (sophie-therese.liebich@suchthilfe.at): no conflicts of interest. David Bauer (david.bauer@meduniwien.ac.at): received travel support from Gilead and Abbvie and speaker fees from Abbvie. Lukas Burghart (lukas.burghart@gesundheitsverbund.at): no conflicts of interest. Leonard Brinkmann (leonard-ruben.brinkmann@gesundheitsverbund.at): no conflicts of interest. Enisa Gutic, Austria (enisa.gutic@extern.gesundheitsverbund.at): received travel support from Gilead and AbbVie. Thomas Reiberger, Austria (thomas.reiberger@meduniwien.ac.at): received grant support from Abbvie, Boehringer-Ingelheim, Gilead, MSD, Philips Healthcare, Gore; speaking honoraria from Abbvie, Gilead, Gore, Intercept, Roche, MSD; consulting/advisory board fee from Abbvie, Bayer, Boehringer-Ingelheim, Gilead, Intercept, MSD, Siemens; and travel support from Boehringer-Ingelheim, Gilead and Roche. Hans Haltmayer, Austria (hans.haltmayer@suchthilfe.at): no conflicts of interest. - Michael Gschwantler, Austria (michael.gschwantler@gesundheitsverbund.at): received grant support from Abbvie, Gilead and MSD; speaking honoraria from Abbvie, Gilead, Intercept, Janssen, BMS, Roche, Norgine, AstraZeneca, Falk, Shionogi, and MSD; consulting/advisory board fees from Abbvie, Gilead, Intercept, Janssen, BMS, Roche, Alnylam, Norgine, AstraZeneca, Falk, Shionogi and MSD; and travel support from Abbvie and Gilead.
- Open Access
- 4 June 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (6) , e0252274
Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy
We evaluated the effectiveness of sofosbuvir/velpatasvir (SOF/VEL) in difficult-to-treat PWIDs with presumed high risk for non-adherence to antiviral therapy using an innovative concept involving their opioid agonist therapy (OAT) facility. N = 221 patients (m/f: 168/53; median age: 44.7 years (IQR 16.9); HCV-genotype 3: 45.2%; cirrhosis: 33.9%) treated with SOF/VEL were included. PWIDs at high risk for non-adherence to DAA therapy (n = 122) received HCV treatment alongside OAT under the supervision of medical staff ("directly observed therapy", DOT). These patients were compared to patients with presumed excellent drug compliance, who were treated in a "standard setting" (SS) of SOF/VEL prescription at a tertiary care center (n = 99). DOT-patients (n = 122/221; 55.2%) were younger than SS-patients (median age: 41.3 vs. 53.0 years), all had psychiatric comorbidities and most had a poor socioeconomic status. 83/122 (68.0%) reported ongoing intravenous drug use. Within the DOT-group, SVR12 was achieved in 99.1% (95% CI: 95.0–100; n = 109/110) with one patient experiencing treatment failure, while n = 12/122 (9.8%) patients were excluded due to loss of follow-up (FU). 5 patients showed HCV reinfection after achieving SVR12. SS-patients achieved SVR in 96.6% (95% CI: 90.3–99.3%; n = 84/87) after exclusion of 10/99 (10.1%) patients who were lost to FU and 2 patients who died prior to SVR12 due to reasons not related to DAA therapy. SOF/VEL given as DOT along with OAT in PWIDs at high risk of non-adherence to antiviral therapy including those with ongoing intravenous drug use resulted in excellent SVR rates similar to patients with presumed “excellent compliance” under standard drug intake.
- 4 June 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (6) , e0252274
Open AccessDirectly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy
We evaluated the effectiveness of sofosbuvir/velpatasvir (SOF/VEL) in difficult-to-treat PWIDs with presumed high risk for non-adherence to antiviral therapy using an innovative concept involving their opioid agonist therapy (OAT) facility. N = 221 patients (m/f: 168/53; median age: 44.7 years (IQR 16.9); HCV-genotype 3: 45.2%; cirrhosis: 33.9%) treated with SOF/VEL were included. PWIDs at high risk for non-adherence to DAA therapy (n = 122) received HCV treatment alongside OAT under the supervision of medical staff ("directly observed therapy", DOT). These patients were compared to patients with presumed excellent drug compliance, who were treated in a "standard setting" (SS) of SOF/VEL prescription at a tertiary care center (n = 99). DOT-patients (n = 122/221; 55.2%) were younger than SS-patients (median age: 41.3 vs. 53.0 years), all had psychiatric comorbidities and most had a poor socioeconomic status. 83/122 (68.0%) reported ongoing intravenous drug use. Within the DOT-group, SVR12 was achieved in 99.1% (95% CI: 95.0–100; n = 109/110) with one patient experiencing treatment failure, while n = 12/122 (9.8%) patients were excluded due to loss of follow-up (FU). 5 patients showed HCV reinfection after achieving SVR12. SS-patients achieved SVR in 96.6% (95% CI: 90.3–99.3%; n = 84/87) after exclusion of 10/99 (10.1%) patients who were lost to FU and 2 patients who died prior to SVR12 due to reasons not related to DAA therapy. SOF/VEL given as DOT along with OAT in PWIDs at high risk of non-adherence to antiviral therapy including those with ongoing intravenous drug use resulted in excellent SVR rates similar to patients with presumed “excellent compliance” under standard drug intake.
- Open Access
- 10 March 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (3) , e0229239
Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs—First real world data from Austria
Directly acting antivirals (DAA) against hepatitis C virus (HCV) infection have facilitated sustained virologic response (SVR) rates >90% in clinical studies. Yet, real life data regarding DAA treatment in people who inject drugs (PWIDs) are scarce. We evaluated the effectiveness of glecaprevir/pibrentasvir (G/P) in difficult-to-treat PWIDs with presumed high risk of non-adherence to DAA therapy using the concept of directly observed therapy involving their opioid substitution therapy (OST) facility. N = 145 patients (m/f: 91/54; median age: 41.1 (IQR 19.5) years; HCV-genotype (GT) 1/2/3/4: 82/1/56/5, GT3: 38.6%; cirrhosis: n = 6; 4.1%) treated with G/P were included. PWIDs at high risk for non-adherence to DAA therapy received HCV treatment together with their OST under the supervision of medical staff ("directly observed therapy", DOT). The effectiveness of G/P given as DOT in PWIDs with presumed high risk of non-adherence to DAA therapy was compared to patients with suspected “excellent compliance” in the "standard setting" (SS) of G/P prescription at a tertiary care center and self-managed G/P intake at home. Treatment duration was 8–16 weeks according to the G/P drug label. DOT-patients (n = 74/145; 51.0%) were younger than SS-patients (median 38.7, IQR 12.5 vs. median 50.6, IQR 20.3 years), all had psychiatric co-morbidities and most had a poor socioeconomic status. 50/74 (67.6%) reported ongoing intravenous drug use (IDU). SVR was achieved in n = 70/74 (94.6%) patients with n = 3 being lost to follow-up (FU) and n = 1 showing nonresponse to therapy. SS-patients achieved SVR in 97.2% (69/71) with n = 1 patient being lost to FU and n = 1 patient with GT3 showing HCV relapse. G/P given as DOT along with OST in PWIDs with high risk of non-adherence to DAA therapy resulted in similarly high SVR rates (94.6%) as in patients with presumed “excellent compliance” under standard drug intake.
- 10 March 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (3) , e0229239
Open AccessDirectly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs—First real world data from Austria
Directly acting antivirals (DAA) against hepatitis C virus (HCV) infection have facilitated sustained virologic response (SVR) rates >90% in clinical studies. Yet, real life data regarding DAA treatment in people who inject drugs (PWIDs) are scarce. We evaluated the effectiveness of glecaprevir/pibrentasvir (G/P) in difficult-to-treat PWIDs with presumed high risk of non-adherence to DAA therapy using the concept of directly observed therapy involving their opioid substitution therapy (OST) facility. N = 145 patients (m/f: 91/54; median age: 41.1 (IQR 19.5) years; HCV-genotype (GT) 1/2/3/4: 82/1/56/5, GT3: 38.6%; cirrhosis: n = 6; 4.1%) treated with G/P were included. PWIDs at high risk for non-adherence to DAA therapy received HCV treatment together with their OST under the supervision of medical staff ("directly observed therapy", DOT). The effectiveness of G/P given as DOT in PWIDs with presumed high risk of non-adherence to DAA therapy was compared to patients with suspected “excellent compliance” in the "standard setting" (SS) of G/P prescription at a tertiary care center and self-managed G/P intake at home. Treatment duration was 8–16 weeks according to the G/P drug label. DOT-patients (n = 74/145; 51.0%) were younger than SS-patients (median 38.7, IQR 12.5 vs. median 50.6, IQR 20.3 years), all had psychiatric co-morbidities and most had a poor socioeconomic status. 50/74 (67.6%) reported ongoing intravenous drug use (IDU). SVR was achieved in n = 70/74 (94.6%) patients with n = 3 being lost to follow-up (FU) and n = 1 showing nonresponse to therapy. SS-patients achieved SVR in 97.2% (69/71) with n = 1 patient being lost to FU and n = 1 patient with GT3 showing HCV relapse. G/P given as DOT along with OST in PWIDs with high risk of non-adherence to DAA therapy resulted in similarly high SVR rates (94.6%) as in patients with presumed “excellent compliance” under standard drug intake.